A 34% share-price jump is the market’s blunt way of saying that Option Care Health’s future may be worth considerably more outside the public market. Shares of Option Care Health ($OPCH) jumped 34% on Oct. 6 after McKesson Corp. ($MCK) and Clayton, Dubilier & Rice agreed to acquire the healthcare-services company in a transaction valued at $5.8 billion.

That is not merely another healthcare headline. It is a meaningful signal that strategic buyers and private equity remain willing to deploy substantial capital for established healthcare-services assets. The immediate reaction also gives traders and shareholders a clear reference point: the market is rapidly repricing $OPCH around the proposed transaction, while still leaving the usual questions surrounding completion, timing and deal terms.

The announcement was attributed to the Seeking Alpha wire on Oct. 6, 2026. According to the report, CD&R and McKesson agreed to acquire Option Care Health in a deal valued at $5.8 billion.

Why the 34% move matters

For traders, a 34% move immediately changes the character of the stock. Before the announcement, valuation debates could center on earnings, growth and the company’s position in healthcare services. Once a takeover agreement is disclosed, the central question becomes whether the market price reflects the proposed transaction and whether the deal ultimately closes.

That distinction matters. A takeover price can establish a reference point, but it does not eliminate execution risk. Shareholders evaluating the situation must distinguish between the value implied by the $5.8 billion agreement and the price at which $OPCH shares trade after the announcement. Any gap may reflect uncertainty over closing conditions, timing or the possibility that the transaction does not proceed as expected. The assignment does not provide a separate offer price or a stated premium, so the 34% jump should not be treated as a precise measure of the takeover premium.

Still, the reaction is revealing. A move of this magnitude indicates that investors view the proposed transaction as materially different from the company’s prior standalone path. It also shows how quickly a public healthcare-services company can become the focus of strategic and financial buyers when the right combination of scale and market positioning appears available.

A significant healthcare M&A signal

The $5.8 billion valuation places this transaction firmly among the more consequential healthcare-services deals to watch heading into year-end. McKesson brings strategic scale, while CD&R brings private-equity sponsorship. That combination highlights two sources of buying power operating in the same market: an established healthcare company seeking strategic value and an investment firm willing to commit capital to a major take-private transaction.

The broader message is not that every healthcare-services company is now a takeover candidate. It is that sizeable assets in the sector can attract attention when strategic and financial buyers see value that may not be fully recognized in the public market. For deal watchers, the transaction could become a useful barometer for appetite in healthcare M&A as 2026 moves toward its final quarter.

What comes next for shareholders

The headline numbers are straightforward: $OPCH shares jumped 34%, and McKesson and CD&R agreed to a transaction valued at $5.8 billion. The less straightforward part is the path from announcement to completion. Traders will likely focus on the formal transaction terms and any conditions attached to the agreement, while shareholders will weigh the proposed value against the time and uncertainty involved in waiting for a closing.

The market’s initial response is bullish in tone, but it is not a closing certificate. The 34% reaction suggests investors see substantial transaction value, while the absence of additional deal details in the announcement means the closing framework remains central to the analysis. In classic merger-arbitrage fashion, the spread between current trading levels and the eventual transaction value—if one exists—would reflect the market’s assessment of risk, timing and certainty.

For now, Option Care Health has moved from a standalone healthcare-services story to a $5.8 billion test of strategic M&A appetite. McKesson and CD&R have put a major transaction on the board. The next phase will be determining whether the agreement can convert that headline valuation into a completed takeover.